PeppiLibrary

Metabolic

AOD-9604 peptide reference

Synthetic fragment of human growth hormone. Researched for fat metabolism without GH effects.

Last reviewed May 6, 2026 Human data Not FDA approved
Peppi reviewing AOD-9604 notes
Default dose label300 mcg
Preferred routeSubQ
Frequency label1× daily, often pre-fasted state
Storage window30 days mixed

Evidence snapshot

Human data

Evidence maturityHuman data
Animal studies positive; human Phase 2b trials failed for obesity endpoint

Research chemical (US); cosmetic ingredient in some Australian formulations

Route map

How records are usually labeled

1 SubQ

Rotate sites within abdominal area.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C; freeze for long-term.
After mixRefrigerate 2–8 °C, use within 30 days.
Use-by cue30 days after mixing
Mixed vial window30 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 5 mg vial
Dose 300 mcg
Route SubQ
Review 30d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for AOD-9604. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

AOD-9604 is a 16-amino-acid synthetic fragment corresponding to residues 176-191 of human growth hormone, with an additional N-terminal tyrosine. It was designed to retain the lipolytic (fat-burning) activity of GH while removing growth-promoting effects. It does not activate GH receptors and does not raise IGF-1.

Also known as: Anti-Obesity Drug 9604, hGH 176-191.

Body recomposition adjunctStubborn-fat localisation researchStack with GH secretagogues for lipolytic emphasis

Mechanism and timing snapshot

Stimulates lipolysis and inhibits lipogenesis without binding GH receptors; mechanism appears to act on adipose β3-adrenergic pathways.

Onset label30 min
Catalog onset field, when available.
Half-life label30 min
Plasma half-life ~30 min; downstream lipolytic effects persist longer
Duration label6 hr
Catalog duration field, when available.
subQ Moderate
oral Low — degraded in GI tract

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose300 mcg
Catalog dose range250 mcg - 500 mcg
Default routeSubQ
Frequency label1× daily, often pre-fasted state
Best time labelMorning, fasted — pairs well with fasted cardio.
Food noteTake on empty stomach for clearest lipolytic signal.

Catalog protocol note

300 mcg subQ once daily, ideally morning on empty stomach, for 30–90 days.

Routes and site notes

Available route labelsSubQ
Preferred route labelSubQ
Common site labelsAbdomen
Site rotation noteRotate sites within abdominal area.

Chemistry

SequenceYLRIVQCRSVEGSCGF (Tyr-hGH 177-191)
Amino acids16
Molecular formulaC78H123N23O23S2
Molecular weight1815.1 Da

Vial, reconstitution, and storage

Supply formLyophilized powder
Typical vial size5 mg
DiluentBacteriostatic water
Diluent volume2.5 mL
Concentration note5 mg in 2.5 mL → 0.15 mL = 300 mcg (15 units on a 100-unit insulin syringe).
Before reconstitutionRefrigerate 2–8 °C; freeze for long-term.
After reconstitutionRefrigerate 2–8 °C, use within 30 days.
Reconstituted shelf life30 days
Light sensitiveYes
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Generally well-tolerated
  • Mild injection-site reactions
  • Nausea
  • Headache

Contraindications and warnings

  • Failed Phase 2b trials for obesity in 2007; not approved for human use.
  • Sold as research-only in the US.

Other considerations

  • Does not raise IGF-1 — distinct from GH analogs.
  • Effects on body composition are modest in published research; expectations should be calibrated.

Evidence and regulatory context

Evidence levelAnimal studies positive; human Phase 2b trials failed for obesity endpoint
FDA approvedNo
Regulatory statusResearch chemical (US); cosmetic ingredient in some Australian formulations
Prescription requiredNo
Approved countriesNot listed

Stacking and cycle notes

Stacks well withcjc-1295, ipamorelin
Avoid combining noteNot listed
Typical cycle label8–12
Typical break label4
Cycle guidanceRun alongside a caloric deficit and resistance training; effect is potentiation, not replacement.

Tracking tips

  • Most useful as an adjunct to a structured cut, not a standalone weight-loss tool.
  • Pairs with a GHRH analog if you also want sleep / recovery benefits.
  • Don't expect dramatic results — Phase 2b human data was underwhelming.

References

Track it in Peppi

Keep AOD-9604 records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for AOD-9604?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use AOD-9604?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export AOD-9604 records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026